Pharmaron acquired large production bases and continued to deploy CDMO tracks

Recently, domestic CDMO giant Pharmaron announced that it has successfully acquired Aesica Pharmaceuticals, a subsidiary of Recipharm in Cramlington, UK, aiming to further enhance the overall strength of the small molecule CDMO service platform
.
It is reported that Recipharm is a drug production service provider (CDMO), which can provide various pharmaceutical companies with production services for hundreds of products, including the production of various dosage forms of drugs, the production of clinical trial drugs and APIs, formulation development and medical treatment.
Development and manufacture of device products
.
The production base of Recipharm acquired by Pharmaron is located in Newcastle, UK.
It has a production capacity of more than 100 cubic meters of reactors, and can provide cGMP API production services from pilot to ton commercial scale
.
The production facility has been verified and certified by a number of regulatory agencies, including the US FDA
.
For this acquisition, Pharmaron said that it will further enhance the overall strength of the small molecule CDMO service platform
.
According to the data, Pharmaron Chemical is a life science R&D service company with business all over the world, dedicated to assisting customers to accelerate drug innovation, and providing full-process integrated drug research, development and production services from drug discovery to drug development
.
According to the main business type, it can be divided into four service modules: laboratory service, CMC (small molecule CDMO) service, clinical research service, macromolecule and cell and gene therapy service
.
Financial data shows that Kanglong Chemical’s revenue has increased from 1.
634 billion in 2016 to 5.
134 billion in 2020, with a compound annual growth rate of 33.
13%; profit has also increased from 177 million to 1.
172 billion yuan, with a compound annual growth rate of 60.
45%
.
On October 27, 2021, the company released the third quarterly report for 2021.
In the first three quarters of 2021, the operating income was 5.
302 billion yuan, a year-on-year increase of 47.
84%; the net profit attributable to the parent was 1.
040 billion yuan, a year-on-year increase of 31.
81%.

.
According to the 2020 annual report, 63.
56% of its revenue comes from laboratory services, 23.
80% from CMC services, and 12.
26% from clinical research services; the gross profit is 1.
924 billion yuan, the gross profit margin is 37.
47%, and the net profit margin is 22.
34%
.
As of 2020, the company has set up 11 institutions around the world
.
In China, the main business of its Beijing headquarters is new drug research and development, specifically drug discovery and early drug development related laboratories; the total reactor volume of the Tianjin factory is 176m3, including 20L-8000L reactors
.
Judging from the CDMO track where Pharmaron is located, the CDMO industry is expanding its market scale under the background of specialized division of labor in the pharmaceutical industry
.
Guotai Junan predicts that by 2023, the market size of the global pharmaceutical CDMO industry will reach US$51.
8 billion, and the domestic market will reach US$8.
5 billion
.
At present, the industry market is still relatively scattered, mainly concentrated in Europe, the United States, Japan and other countries.
With the acceleration of the global CDMO R&D and production demand in China, and the gradual supply of engineer bonuses and mid-to-high-end talents, the development prospects of the domestic CDMO industry It is generally optimistic, and giant companies are expected to meet more new opportunities
.
An analysis of the market share of the pharmaceutical R&D outsourcing industry based on the data published in the annual reports of each company shows that in 2020, WuXi AppTec's market share will reach more than 21%; followed by Pharmaron, which will reach about 7.
5%; It is Tigermed with a market share of 6.
14%
.
It can be seen that with the emergence of the blue ocean of the market, the competition among these giant enterprises will become more intense in the future.
Kanglong Chemical will take another step in the layout of the CDMO track through the acquisition of the new production base
.
The industry pointed out that in order to control costs, control risks including technology transfer and quality issues, and save time, large CDMOs in the industry will expand capacity by acquiring small CDMOs, and will also improve by merging with other competitors.
Supply chain efficiency, and this trend of M&A consolidation is expected to continue as the industry matures
.